Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer.
Since the enhanced production of IL-10 by human bronchogenic carcinoma has already been documented, in the present study serum levels of IL-10 were measured serially in patients with lung cancer undergoing radiotherapy. Thirty-one full diagnosed cancer patients underwent the radiotherapy procedures. The interleukin-10 (IL-10) and interleukin-6 (IL-6) serum levels were measured before therapy and after 3, 6 and 12 months after therapy. The interleukins concentrations were evaluated using a solid phase sandwich Enzyme-Linked-Immuno-Sorbent-Assay (ELISA). In all patients the serum levels of IL-10 have been found elevated. Due to the treatment they progressively declined to almost normal ranges in responders, while they remained elevated in non-responders. Serum levels of interleukin-6 have been elevated in the majority of our patients. After 12 months observation they also decreased, mainly in patients responding to the treatment. No correlation between serum IL-10 and IL-6 level has been found. The importance of serum IL-6 determination in lung cancer patients monitoring has already been established. The present study shows, that in spite of still unclear role of IL-10 in the process of carcinogenesis, it may be considered as a prognostic factor in lung cancer.
Wojciechowska-Lacka
A
A
Department of Radiotherapy, Wielkopolska Cancer Center, Poznań, Poland.
Matecka-Nowak
M
M
Adamiak
E
E
Lacki
J K
JK
Cerkaska-Gluszak
B
B
D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D011379:Prognosis; D011859:Radiography; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D015850:Interleukin-6; D016753:Interleukin-10